Freenome and PCSC Merge in $1.1B Deal for Cancer Detection

Health
Health
Definitive Agreement
Definitive Agreement

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

Freenome and Perceptive Capital Solutions Corp Announce $1.1 Billion Business Combination to Advance Blood-Based Cancer Detection

Brisbane, CA, and New York - Freenome Holdings, Inc., an early cancer detection company, and Perceptive Capital Solutions Corp (Nasdaq: PCSC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing, PCSC will redomicile as a Delaware corporation, be renamed Freenome, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol "FRNM". The transaction is anticipated to be completed in the first half of 2026, creating a publicly listed company focused on transforming blood-based multi-cancer detection through an AI/ML-enabled multiomics platform.

... Read on — Members only

About Freenome Holdings, Inc.

Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.

View Company Details

SPAC IPO Calendar
SPAC IPO Events
Scroll to Top